Teva Pharmaceuticals

We’re a leading innovative biopharmaceutical company, enabled by a world-class generics business. Guidelines:

[Teva Pharmaceuticals @TevaUSA]

Teva to advance its anti-IL-15 antibody, designed for quarterly dosing, into Phase 2b development in vitiligo, following encouraging Phase 1b results.
Learn more here: https://t.co/ycV3nRpu53

[Teva Pharmaceuticals @TevaUSA]

As a leader in neuroscience, we are committed to advancing innovative treatments that may help address critical unmet needs for patients living with complex conditions.

Today, Teva announced the submission of a New Drug Application (NDA) to the U.S. FDA for an investigational therapy for pediatric Tourette syndrome.

Learn more: https://t.co/94NLJTYTKR

#TevaPharm $Teva

[Teva Pharmaceuticals @TevaUSA]

@mypuppys15 Thanks for letting us know! Please report any product concerns to our US Quality Department at 888-838-2872 or [email protected].

[Teva Pharmaceuticals @TevaUSA]

At #ATMRD2026, Teva revealed new real-world survey data evaluating the patient- and caregiver-reported impacts of Huntington’s Disease (HD) chorea, which demonstrate how deeply the condition can affect patients and their care partners.

See more: https://t.co/CWxJDF3NPg

[Teva Pharmaceuticals @TevaUSA]

We announced a comprehensive data package at #PsychCongressElevate2026, outlining key insights across the #tardivedyskinesia (TD) disease journey, from initial diagnosis to long-term management.

See more: https://t.co/iPdJWJx0V7

[Teva Pharmaceuticals @TevaUSA]

@booteslamur Thank you for your message. Please visit our local India website where you can submit your contact details and questions: https://t.co/PrQLAEKerI

[Teva Pharmaceuticals @TevaUSA]

As we accelerate the momentum on our #PivotToGrowth strategy, join our live Q3 earnings call with President and CEO Richard Francis and the Teva leadership team, on Wednesday, November 5.

Save the date:
https://t.co/kgS3MHyefP

#QuarterlyResults #Q3Results #Earnings #Tevapharm

[Teva Pharmaceuticals @TevaUSA]

Teva reveals the latest from our IMPACT-TD Registry, presented at #APAAM2026, uncovering a critical gap in diagnosing #TardiveDyskinesia (TD) in patients with underlying mood disorders.

See more: https://t.co/C5Fi4oRjFV

[Teva Pharmaceuticals @TevaUSA]

We are reporting our Q1 2026 results as we continue our transformation into a leading biopharma company: https://t.co/zvOuAJwuZd

Forward-looking statements are subject to the cautionary note included in our Q1 2026 press release.

#QuarterlyResults #Earnings $Teva

[Teva Pharmaceuticals @TevaUSA]

JUST ANNOUNCED: Teva enters into an agreement to acquire Emalex Biosciences, advancing our #PivotToGrowth strategy and expanding our late-stage neuroscience pipeline.

See more: https://t.co/ElGWpgjbqZ

$TEVA

[Teva Pharmaceuticals @TevaUSA]

Tune in to our Q1 2026 earnings call with CEO Richard Francis and the Teva leadership team on Wednesday, April 29.
Save the date: https://t.co/DPT2kz3aLs
#QuarterlyResults #Q1Results #Earnings $Teva
Forward-looking statements are subject to the cautionary note included in our Q1 2026 press release.

[Teva Pharmaceuticals @TevaUSA]

Today, we launched Home Ground™ Schizophrenia Community, developed in collaboration with people living with schizophrenia and their care partners. Learn more about Home Ground™ and our continuing commitment to the schizophrenia community: https://t.co/R9HCWSk2tn

[Teva Pharmaceuticals @TevaUSA]

An important day for #Teva as the @US_FDA approves our first home-grown biosimilar, for a range of bone conditions, and the #FDA + @EMA_News accept for review our proposed biosimilar candidate for allergic diseases and atopic conditions. More: https://t.co/2U4cCKMm3E

$TEVA

[Teva Pharmaceuticals @TevaUSA]

@keywestergren Thank you for your message. Please contact our Customer Service team for questions or issues regarding our medicines in the US:Tel: 888-TEVA-USA (888-838-2872) or email: [email protected]

[Teva Pharmaceuticals @TevaUSA]

@caliaurora Thank you for your message. Please contact our Customer Service team for questions or issues regarding our medicines in the US:Tel: 888-TEVA-USA (888-838-2872) or email: [email protected]

[Teva Pharmaceuticals @TevaUSA]

The @US_FDA has accepted Teva’s NDA for a potential new treatment option for adults living with #schizophrenia

Learn more here: https://t.co/svIAWQj1AR

#PivotToGrowth $TEVA

[Teva Pharmaceuticals @TevaUSA]

TEVA PIPELINE UPDATE: New long-term maintenance data announced for our investigational treatment for ulcerative colitis and Crohn’s disease. Read more: https://t.co/EMiGg8o4Or

#TevaPharm #Teva

[Teva Pharmaceuticals @TevaUSA]

@LadyZ_613 Thanks for letting us know! Please report any product concerns to our US Quality Department at 888-838-2872 or [email protected].

[Teva Pharmaceuticals @TevaUSA]

Our Q4 and full year 2025 earnings call is starting in 30 minutes. Join to hear about Teva's business performance and plans ahead. Forward-looking statements are subject to the cautionary note included in our Q4 and full year 2025 press release.
https://t.co/Xj2yrjFKHR

$Teva

[Teva Pharmaceuticals @TevaUSA]

On Wednesday, January 28, tune in to our live Q4 and FY 2025 earnings call with CEO Richard Francis and the Teva leadership team.

Save the date:
https://t.co/BRIJaB7uPO

#QuarterlyResults #Q4Results #Earnings $Teva

[Teva Pharmaceuticals @TevaUSA]

As we accelerate our transformation into a leading biopharma company, sharing our Q4 and FY 2025 results.

https://t.co/PtPrkJSF6h

Forward-looking statements are subject to the cautionary note included in our Q4 and FY 2025 press release.

#QuarterlyResults #Earnings $Teva

[MM+M @MMMnews]

Actor Will Forte details brother-in-law’s Huntington’s disease in Teva campaign https://t.co/KmMVGbZHTY @TevaUSA